Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Issued (2021 - 2025)

ARS Pharmaceuticals' Shares Issued history spans 5 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 16.11% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $5.7 million, up 88.36%, while the annual FY2025 figure was $5.7 million, 88.36% up from the prior year.
  • Shares Issued for Q4 2025 was $1.8 million at ARS Pharmaceuticals, up from $479000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $2.9 million in Q2 2023 and bottomed at -$1.0 million in Q4 2021.
  • The 5-year median for Shares Issued is $702500.0 (2024), against an average of $907500.0.
  • The largest annual shift saw Shares Issued soared 894.43% in 2023 before it plummeted 80.9% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$1.0 million in 2021, then skyrocketed by 127.85% to $283000.0 in 2022, then skyrocketed by 537.81% to $1.8 million in 2023, then dropped by 15.07% to $1.5 million in 2024, then rose by 16.11% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Shares Issued are $1.8 million (Q4 2025), $479000.0 (Q3 2025), and $2.7 million (Q2 2025).